Shanxi Baotai Pharmaceutical

Shanxi Baotai Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company established in 1999 and headquartered in Taiyuan, Shanxi Province. The company specializes in the development, manufacturing, and marketing of active pharmaceutical ingredients (APIs) and finished dosage forms, with a core focus on metabolic, cardiovascular, and gastrointestinal therapeutics. Its commercial portfolio features established products such as Domperidone for nausea and Halcinonide for dermatological conditions, while its clinical pipeline includes small molecule candidates like Pitavastatin Calcium and Vonoprazan Fumarate currently undergoing bioequivalence studies. Shanxi Baotai operates large-scale manufacturing facilities compliant with Good Manufacturing Practice (GMP) standards and serves as a significant supplier in the global API market. The company gained international visibility in the early 2010s due to proposed strategic merger interest from US-based Radient Pharmaceuticals.